The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer.
 
Quincy S. Chu
Honoraria - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Lilly; Merck; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Lilly; Merck; Novartis; Pfizer; Roche; Takeda
Research Funding - AstraZeneca; Boehringer Ingelheim
 
Derek J. Jonker
No Relationships to Disclose
 
Diane M. Provencher
Leadership - AstraZeneca
Honoraria - AstraZeneca; Roche/Genentech
Consulting or Advisory Role - AstraZeneca
Travel, Accommodations, Expenses - Roche/Genentech
 
Wilson H. Miller
Honoraria - Bristol-Myers Squibb; Merck; Novartis; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Mylan; Novartis; Roche
Research Funding - Bristol-Myers Squibb; Esperas Pharma; GlaxoSmithKline; Incyte; MedImmune; Merck; Novartis; Pfizer; Roche; Sanofi
Travel, Accommodations, Expenses - Pfizer
 
Nathaniel Bouganim
Consulting or Advisory Role - AstraZeneca; Lilly; Novartis; Pfizer; Roche
 
Anthony Frank Shields
Consulting or Advisory Role - Caris Life Sciences; ImaginAb; TransTarget
Speakers' Bureau - Caris Life Sciences
Research Funding - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Boston Biomedical; Caris Life Sciences; Daiichi Sankyo; Eisai; Esperas Pharma; Esperas Pharma; Exelixis; Five Prime Therapeutics; H3 Biomedicine; Halozyme; ImaginAb; Incyte; Inovio Pharmaceuticals; Lexicon; LSK BioPharma; MSK Pharma; Nouscom; Plexxikon; Taiho Pharmaceutical; Torque; Xencor
Travel, Accommodations, Expenses - Caris Life Sciences; GE Healthcare; ImaginAb; Inovio Pharmaceuticals; TransTarget
 
Geoffrey Shapiro
Consulting or Advisory Role - Almac Diagnostics; Angiex; Artios; Astex Pharmaceuticals; Atrin Pharmaceuticals; Bayer; Bicycle Therapeutics; Boehringer Ingelheim; Boehringer Ingelheim; Concarlo; Cybrexa Therapeutics; Daiichi Sankyo; Fusion Pharmaceuticals; G1 Therapeutics; Ipsen; Lilly; Merck Serono; Pfizer; Roche; Seagen; Sierra Oncology
Research Funding - Aileron Therapeutics (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CanBas (Inst); Cellceutix (Inst); Clovis Oncology (Inst); Covidien (Inst); Curis (Inst); Cyclacel (Inst); Esperas Pharma (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PTC Therapeutics (Inst); Puma Biotechnology (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Sierra Oncology (Inst); Syros Pharmaceuticals (Inst); Tensha Therapeutics (Inst); Tesaro (Inst); Vertex (Inst)
Patents, Royalties, Other Intellectual Property - Patent #: 9872874 Title: Dosage regimen for sapacitabine and seliciclib Issue Date: 1/23/2018; Provisional Patent #:62/538,319 Title: Compositions and methods for predicting response and resistance to CDK4/6 inhibition Filed: 7/28/17
Travel, Accommodations, Expenses - Bayer; Bicycle Therapeutics; G1 Therapeutics; Lilly; Pfizer; Sierra Oncology
 
Michael B. Sawyer
Honoraria - Baxter; Bristol-Myers Squibb; Celgene; Fresenius Kabi; ipsen; Ipsen; LEO Pharma; Merck; Mylan; Novartis; Novartis Canada Pharmaceuticals Inc; nutricia; pfizer; Sanofi; Shire; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Celgene; Immuneering; Ipsen; Ipsen; LEO Pharma; Nutricia; Pfizer; Yinuoke
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Lilly (Inst); Pfizer (Inst); Rexahn Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - My lab discovered that all the competitive tyrosine kinase inhibitors such as sunitinib and gefitinib have additional pharmacological properties. This additional pharmacologic property causes intestinal epithelial cells to active their chloride channels l
Travel, Accommodations, Expenses - Amgen; Ipsen; LEO Pharma; Novartis Canada Pharmaceuticals Inc; Nutricia; pfizer
 
Stephanie Lheureux
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Merck; Roche/Genentech
Research Funding - AstraZeneca (Inst); Merck (Inst); Regeneron (Inst); Roche/Genentech (Inst); Tesaro (Inst)
 
Vanessa Samouelian
No Relationships to Disclose
 
Walter H. Gotlieb
Honoraria - AstraZeneca; AstraZeneca; Intuitive Surgical; Merck; Minogue Medical; Pfizer; Roche Canada
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - AstraZeneca
Research Funding - AstraZeneca (Inst); Intuitive Surgical (Inst)
Travel, Accommodations, Expenses - Minogue Medical
 
Khashayar Esfahani
No Relationships to Disclose
 
Sara L. Zaknoen
No Relationships to Disclose
 
Patricia S Smith
Employment - Lilly
Travel, Accommodations, Expenses - Lilly
 
Joel Owen
Employment - Cognigen Corporation
Stock and Other Ownership Interests - Simulations Plus
 
Caroline Fortier
Employment - Esperas Pharma; PRCL Research
Leadership - AurKa Pharma; Esperas Pharma; GLWL Research; Kaneq Bioscience; Ocellaris Pharma; PRCL Research
Stock and Other Ownership Interests - BFT Cancer; InflammatoRx
Consulting or Advisory Role - AurKa Pharma; Esperas Pharma; GLWL Research; Kaneq Bioscience; Ocellaris Pharma; PRCL Research
Travel, Accommodations, Expenses - AurKa Pharma; Esperas Pharma; Ocellaris Pharma
 
John R. Stille
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Darcy Vincett
Employment - Stericycle (I)
Stock and Other Ownership Interests - Stericycle (I)
 
Amit M. Oza
Honoraria - Intas
Consulting or Advisory Role - Immunogen; Merck KGaA
Research Funding - AstraZeneca (Inst); Immunovaccine (Inst)
Travel, Accommodations, Expenses - AstraZeneca
Other Relationship - AstraZeneca; Clovis Oncology; Clovis Oncology; Merck; Tesaro